Clinical trial
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic…
NCT00318552 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00318552 |
|---|---|
| Title | Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. |
| Official title | Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. An Open, Randomized Multi-center Study. |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Sepsis |
| Intervention type | Drug |
| Interventions | Meropenem |
| Enrollment | 160 |
| Start date | Jan 1, 2002 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Apr 27, 2006 |
| Last update posted | Sep 1, 2017 |
| Countries | Hungary |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: